The China lung cancer screening market size was estimated at USD 610.38 Million in 2025, and is projected to reach USD 1.49 billion by 2033, growing at a CAGR of 11.83% from 2025 to 2033. Several key factors drive market growth, including the high prevalence of lung cancer, advances in screening technology, supportive government policies, and increasing awareness about early detection.According to the Shanghai Municipal People's Government, in June 2024, lung cancer was observed as one of the most common and deadliest tumors in China, with approximately 800,000 new cases reported annually and around 70.0% of patients diagnosed at advanced or terminal stages, highlighting the urgent need for effective screening solutions to improve early diagnosis and treatment outcomes.
Lung cancer is the leading cause of cancer incidence and mortality worldwide, and China carries the heaviest burden. Each year, an estimated 1.06 million new cases and 0.73 million deaths are attributed to lung cancer in the country, underscoring its status as a formidable public health challenge. Survival outcomes are strongly linked to stage at diagnosis: patients detected at stage IA have a 5-year survival rate of ~82%, compared to just ~7% in stage IVB, making early detection critical.
Historically, lung cancer in China has been diagnosed late, as early-stage disease presents few symptoms. Randomized controlled trials such as NLST (U.S.) and NELSON (Europe) demonstrated that low-dose CT (LDCT) screening can significantly reduce mortality. However, conventional LDCT presents challenges of false positives, overdiagnosis, and missed detection in high-risk groups not covered by international criteria. China has advanced localized screening protocols tailored to its population to address this. Risk factor profiling in western China-covering smoking, COPD, pulmonary fibrosis, and prior malignancies-has enabled more precise identification of high-risk cohorts.
This product will be delivered within 1-3 business days.
Lung cancer is the leading cause of cancer incidence and mortality worldwide, and China carries the heaviest burden. Each year, an estimated 1.06 million new cases and 0.73 million deaths are attributed to lung cancer in the country, underscoring its status as a formidable public health challenge. Survival outcomes are strongly linked to stage at diagnosis: patients detected at stage IA have a 5-year survival rate of ~82%, compared to just ~7% in stage IVB, making early detection critical.
Historically, lung cancer in China has been diagnosed late, as early-stage disease presents few symptoms. Randomized controlled trials such as NLST (U.S.) and NELSON (Europe) demonstrated that low-dose CT (LDCT) screening can significantly reduce mortality. However, conventional LDCT presents challenges of false positives, overdiagnosis, and missed detection in high-risk groups not covered by international criteria. China has advanced localized screening protocols tailored to its population to address this. Risk factor profiling in western China-covering smoking, COPD, pulmonary fibrosis, and prior malignancies-has enabled more precise identification of high-risk cohorts.
China Lung Cancer Screening Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the China lung cancer screening market report based on cancer, diagnosis, and end use:Cancer Outlook (Revenue, USD Million, 2021-2033)
- Non-small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
Diagnosis Outlook (Revenue, USD Million, 2021-2033)
- Low Dose Spiral CT Scan
- Chest X-ray
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals and Clinics
- Diagnostic Centers
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Lung Cancer Screening Market Variables, Trends & Scope
Chapter 4. China Lung Cancer Screening Market: Cancer Estimates & Trend Analysis
Chapter 5. China Lung Cancer Screening Market: Diagnosis Estimates & Trend Analysis
Chapter 6. China Lung Cancer Screening Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this China Lung Cancer Screening market report include:- Biodesix
- DELFI Diagnostics, Inc.
- GE HealthCare
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- CANON MEDICAL SYSTEMS CORPORATION
- Medtronic
- Shanghai United Imaging Healthcare Co., LTD
- Freenome Holdings, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 610.38 Million |
| Forecasted Market Value ( USD | $ 1490 Million |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | China |
| No. of Companies Mentioned | 11 |
